Drugs / PACLITAXEL DOCOSAHEXAENOIC ACID
PACLITAXEL DOCOSAHEXAENOIC ACID
also known as
Taxoprexin · DHA-paclitaxel · Taxoperxin · DHA-Paclitacel · Docosahexaenoic acid (DHA)-paclitaxel · Paclitaxel-dha
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 27 trials | ||||||
| Phase 2 | NCT00422877 | Jan 2007 → Mar 2008 | liver cancer | American Regent, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00244816 | Oct 2005 → Jun 2008 | metastatic melanoma | American Regent, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00249262 | Oct 2005 → Apr 2007 | metastatic melanoma | American Regent, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00024375 | Jun 2001 → ? | malignant pancreatic neoplasm | Theradex | Unknown | No outcome recorded |
| Phase 2 | NCT00024401 | May 2001 → ? | colorectal cancer | Theradex | Unknown | No outcome recorded |
| Phase 2 | NCT00024388 | Apr 2001 → ? | kidney cancer | Theradex | Unknown | No outcome recorded |
| Phase 2 | NCT00024414 | Apr 2001 → ? | prostate cancer | Theradex | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00243867 | Nov 2005 → Aug 2008 | non-small cell lung carcinoma | American Regent, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00087776 | Dec 2002 → Oct 2007 | melanoma | American Regent, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PACLITAXEL DOCOSAHEXAENOIC ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297441 ↗ |
| Known as | DHA-Paclitacel | “Phase II Open-Label Study of Taxoperxin (DHA-Paclitacel) Injection by 2-Hour Intravenous Infusion in Patients With Metastatic Cancer of the Colon/Rectum” NCT00024401 ↗ |
| Known as | DHA-paclitaxel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00024414 ↗ |
| Known as | Docosahexaenoic acid (DHA)-paclitaxel | “Docosahexaenoic acid (DHA)-paclitaxel” NCT00249262 ↗ |
| Known as | Paclitaxel-dha | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297441 ↗ |
| Known as | Taxoperxin | “Phase II Open-Label Study of Taxoperxin (DHA-Paclitacel) Injection by 2-Hour Intravenous Infusion in Patients With Metastatic Cancer of the Colon/Rectum” NCT00024401 ↗1“Phase II Open-Label Study of Taxoperxin (DHA-Paclitaxel) Injection by 2 Hour Intravenous Infusion in Patients With Metastatic Cancer of the Pancreas” NCT00024375 ↗ |
| Known as | Taxoprexin | “Phase II Open-Label Study of Taxoprexin (DHA-Paclitaxel) Injection by 2-Hour Intravenous Infusion In Patients With Metastatic, Locally Advanced, or Unresectable Renal Cell Carcinoma” NCT00024388 ↗6“Phase II Open-Label Study of Taxoprexin (DHA-Paclitaxel) Injection by 2-Hour Intravenous Infusion in Patients With Metastatic Hormone-Refractory Prostate Cancer” NCT00024414 ↗ |
| Modality | Small molecule | — CHEMBL4297441 ↗ |
| Route | Intravenous | “Patients receive DHA-paclitaxel IV over 2 hours on day 1.” NCT00024375 ↗ |